174 related articles for article (PubMed ID: 33811375)
21. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA.
Wong DK; Seto WK; Cheung KS; Chong CK; Huang FY; Fung J; Lai CL; Yuen MF
Liver Int; 2017 Jul; 37(7):995-1001. PubMed ID: 27992681
[TBL] [Abstract][Full Text] [Related]
22. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk.
Hsu YC; Nguyen MH; Mo LR; Wu MS; Yang TH; Chen CC; Tseng CH; Tai CM; Wu CY; Lin JT; Tanaka Y; Chang CY
Aliment Pharmacol Ther; 2019 Jan; 49(1):107-115. PubMed ID: 30450681
[TBL] [Abstract][Full Text] [Related]
23. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.
Testoni B; Lebossé F; Scholtes C; Berby F; Miaglia C; Subic M; Loglio A; Facchetti F; Lampertico P; Levrero M; Zoulim F
J Hepatol; 2019 Apr; 70(4):615-625. PubMed ID: 30529504
[TBL] [Abstract][Full Text] [Related]
24. New Biomarkers of Chronic Hepatitis B.
Mak LY; Seto WK; Fung J; Yuen MF
Gut Liver; 2019 Nov; 13(6):589-595. PubMed ID: 30919601
[TBL] [Abstract][Full Text] [Related]
25. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy.
Cheung KS; Seto WK; Wong DK; Lai CL; Yuen MF
J Viral Hepat; 2017 Aug; 24(8):654-661. PubMed ID: 28185363
[TBL] [Abstract][Full Text] [Related]
26. End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients.
Brakenhoff SM; de Knegt RJ; van Campenhout MJH; van der Eijk AA; Brouwer WP; van Bömmel F; Boonstra A; Hansen BE; Berg T; Janssen HLA; de Man RA; Sonneveld MJ
J Microbiol Immunol Infect; 2023 Feb; 56(1):31-39. PubMed ID: 35941076
[TBL] [Abstract][Full Text] [Related]
27. Kinetics and Value of Hepatitis B Core-Related Antigen in Patients with Chronic Hepatitis B Virus Infection during Antiviral Treatment.
Sandmann L; Bremer B; Ohlendorf V; Jaroszewicz J; Wedemeyer H; Cornberg M; Maasoumy B
Viruses; 2024 Feb; 16(2):. PubMed ID: 38400031
[TBL] [Abstract][Full Text] [Related]
28. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.
Kuo YH; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
Hepatol Int; 2021 Apr; 15(2):301-309. PubMed ID: 33665773
[TBL] [Abstract][Full Text] [Related]
29. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA.
Chen EQ; Wang ML; Tao YC; Wu DB; Liao J; He M; Tang H
J Viral Hepat; 2019 May; 26(5):586-595. PubMed ID: 30632235
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis B Core-Related Antigen is a Biomarker for off-Treatment Relapse After Long-Term Nucleos(t)ide Analog Therapy in Patients with Chronic Hepatitis B.
Liao G; Ding X; Xia M; Wu Y; Chen H; Fan R; Zhang X; Cai S; Peng J
Int J Gen Med; 2021; 14():4967-4976. PubMed ID: 34483685
[TBL] [Abstract][Full Text] [Related]
31. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcome after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients who achieved HBsAg seroclearance.
Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Saitoh S; Arase Y; Kobayashi M; Kumada H
J Gastroenterol; 2024 Jan; 59(1):34-44. PubMed ID: 37837569
[TBL] [Abstract][Full Text] [Related]
33. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B.
Chuaypen N; Posuwan N; Payungporn S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
Liver Int; 2016 Jun; 36(6):827-36. PubMed ID: 26678018
[TBL] [Abstract][Full Text] [Related]
34. The role of hepatitis B core-related antigen in predicting hepatitis B virus recurrence after liver transplantation.
Yu J; Ye Y; Liu J; Xu Y; Lou B; Zhu J; Sheng X; Feng X; Pan Q; Yang J; Cao H; Li L
Aliment Pharmacol Ther; 2019 Nov; 50(9):1025-1036. PubMed ID: 31339175
[TBL] [Abstract][Full Text] [Related]
35. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients.
Suzuki F; Miyakoshi H; Kobayashi M; Kumada H
J Med Virol; 2009 Jan; 81(1):27-33. PubMed ID: 19031469
[TBL] [Abstract][Full Text] [Related]
36. Quantitative Measurement of Serum HBcrAg Can Be Used to Assess the Feasibility of Safe Discontinuation of Antiviral Therapy for Chronic Hepatitis B.
Wang YH; Tang H; Chen EQ
Viruses; 2024 Mar; 16(4):. PubMed ID: 38675872
[TBL] [Abstract][Full Text] [Related]
37. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation.
Matsuzaki T; Tatsuki I; Otani M; Akiyama M; Ozawa E; Miuma S; Miyaaki H; Taura N; Hayashi T; Okudaira S; Takatsuki M; Isomoto H; Takeshima F; Eguchi S; Nakao K
J Gastroenterol Hepatol; 2013 Jul; 28(7):1217-22. PubMed ID: 23432697
[TBL] [Abstract][Full Text] [Related]
38. Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation.
Suzuki T; Inoue T; Matsuura K; Kusumoto S; Hagiwara S; Ogawa S; Yagi S; Kaneko A; Fujiwara K; Watanabe T; Aoyagi K; Urata Y; Tamori A; Kataoka H; Tanaka Y
J Gastroenterol; 2022 Jul; 57(7):486-494. PubMed ID: 35478052
[TBL] [Abstract][Full Text] [Related]
39. The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review.
Liu J; Li T; Zhang L; Xu A
Hepatology; 2019 Sep; 70(3):1045-1055. PubMed ID: 30561829
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of HBV serological markers in treatment-naïve HBV mono-infected patients and HBV-HIV co-infected patients.
Jiang B; Su R; Ren D; Zheng X; Cao Y; Mi Y; Wang F; Ma P
Virus Res; 2020 Dec; 290():198117. PubMed ID: 32800804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
